InstalabLoading...
InstalabLoading...
Knowing you got vaccinated or had COVID-19 tells you almost nothing about how well your body is currently equipped to handle the virus. Two people with identical vaccine schedules can have wildly different antibody levels six months later, and that difference matters: higher antibody levels track with lower risk of symptomatic infection and severe outcomes.
This test puts a number on your immune protection. It does not guarantee you will not catch COVID-19 again, but it gives you an objective measure of where your immunity stands today, so you can decide whether to time a booster, take extra precautions before high-risk events, or simply track how your levels change over time.
Your immune system makes proteins called antibodies (specifically a type called IgG, the main long-lasting antibody in your blood) that latch onto the spike protein, the part of the virus that lets it enter your cells. This test counts those spike-targeting antibodies in your blood and reports a number, usually in units per milliliter (U/mL) or binding antibody units per milliliter (BAU/mL, an internationally standardized unit).
Higher numbers generally mean stronger humoral immunity (the antibody-based part of your defense). The level tracks closely with neutralizing activity, the functional ability of antibodies to block the virus from entering your cells, with reported correlations of around 0.8 to 0.9 across multiple commercial platforms. That means in most people, a higher reading on this test predicts a higher capacity to neutralize the virus.
One important point: this test detects antibodies from either past infection or vaccination. It does not distinguish between the two. If you want to know whether you have had a natural infection (versus only being vaccinated), you need a separate nucleocapsid antibody test.
A real-world study of 26,844 people found that higher spike antibody levels were associated with substantially lower risk of symptomatic infection and severe outcomes over 12 months.
Levels at or above 2500 U/mL were linked to a 62 to 87 percent reduction in risk over that period. People below the assay's cutoff had the highest infection rates.
Variant-specific antibody levels measured in 2618 people in a separate large population study also showed an inverse relationship: as antibody levels rose, infection risk fell, with stronger predictive value when the antibodies were matched to the currently circulating variant.
The connection between antibody levels and severity of any breakthrough infection is also well documented. In a retrospective cohort of 1665 people, levels below 500 U/mL were associated with an increased risk of severe COVID-19, suggesting this is a useful working threshold for someone trying to avoid hospitalization.
Among 1152 hospitalized adults, lower spike antibody levels at admission were independently linked to higher in-hospital mortality. A separate analysis of 80 vaccinated people hospitalized with breakthrough infection found that higher antibody levels at admission predicted survival.
In a study of 195,446 people, having any detectable spike antibodies was associated with a 44 percent reduction in subsequent infection risk and an 80 percent reduction in serious adverse outcomes.
If you take medications that suppress your immune system, this test takes on extra weight. The MELODY study followed 18,575 immunosuppressed adults and found that those with detectable spike antibodies had measurably lower rates of infection and hospitalization compared to those without.
Up to 13 percent of vaccinated people may not produce antibody levels above protective thresholds, and these non-responders carry higher risk of persistent virus and long COVID. Identifying yourself in this group is something a single test can do, and the consequences of finding out are concrete: your doctor may recommend additional booster doses, monoclonal antibody preventives, or behavioral precautions you would otherwise skip.
There is no universally agreed-upon protective threshold. Different assays from different manufacturers (Roche, Abbott, Siemens, DiaSorin, Ortho) produce systematically different numbers even when converted to the standardized BAU/mL units, with Roche often reporting values 2.4 to 2.8 times higher than other platforms. The ranges below come from published studies and are illustrative orientation, not universal targets. Your lab will likely use slightly different cutpoints.
| Tier | Range (U/mL or BAU/mL) | What It Suggests |
|---|---|---|
| Low or absent | Below 500 U/mL | Higher risk of severe COVID-19 if infected; consider booster |
| Moderate | 500 to 2500 U/mL | Some protection, but room to improve, especially before high-risk exposures |
| High | Above 2500 U/mL | Linked to 62 to 87 percent lower risk of symptomatic infection over 12 months |
For immunocompromised adults, one study identified 148 BAU/mL as a useful working threshold across multiple assays. A more conservative threshold of 1200 BAU/mL has been proposed for adults with coronary artery disease, where antibody levels predicted outcomes better than vaccination status alone. Compare your results within the same lab and assay over time, since switching platforms can produce misleading apparent changes.
Spike antibody levels are not static. After a vaccine dose or infection, levels rise sharply over the first 2 to 3 weeks, peak, then decline over months. A single reading is just a snapshot; the trend is what tells you whether your immunity is holding, building, or fading.
Get a baseline now. If you make a change like adding a booster, retest in 4 to 6 weeks to see whether your numbers actually responded. If you are tracking the durability of existing immunity, retest every 6 to 12 months. People on immunosuppressive medications, transplant recipients, and adults over 65 should test more often, since responses fade faster and vary more in these groups.
If your level comes back low or undetectable despite recent vaccination or infection, the next step depends on context. For most people, the answer is to consider an additional vaccine dose and retest in 4 to 6 weeks to confirm a response. If you are immunosuppressed and remain low after a booster, that is a meaningful finding: discuss preventive monoclonal antibody therapy and behavioral adjustments with your physician.
If your level is high, that is reassuring but not a free pass. No threshold guarantees sterilizing protection, particularly as new variants evolve. Pair this test with a nucleocapsid antibody test if you want to know whether you have had a natural infection, and consider repeating both at the same lab in 6 to 12 months.
A standard COVID-19 PCR or antigen test tells you whether you are infected right now. This antibody test tells you whether your immune system has been trained to fight the virus and how strong that training currently is. The two answer different questions and should not be substituted for each other.
A nucleocapsid antibody test, often offered alongside this one, detects antibodies to a different part of the virus that your body only makes after an actual infection, not from spike-only vaccines. Pairing both tests lets you separate vaccine-induced from infection-induced immunity.
Evidence-backed interventions that affect your COVID Spike Antibody level
SARS-CoV-2 Semi-Quant Spike Ab is best interpreted alongside these tests.